RP Scherer Softgel Technologies

Biotechnology company exploring novel therapeutics for neuroscience indications

An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe paediatric genetic disease.

However, numerous drug delivery challenges threatened the realisation of the fast-track status designation they had received due to promising early stage results.

By partnering with Catalent and leveraging our proprietary RP Scherer Softgel technology, the customer was able to overcome a number of potential hurdles and expeditiuosly enter the Phase II/III clinical trial.

More About This Company